Table 3.
Univariable Cox regression of loco–regional tumour control for clinical parameters and the identified two metagenes in the matched PORT and PORT-C cohorts (n = 108). Significant p-values are marked in bold.
| Parameter | PORT Cohort | PORT-C Cohort | ||||
|---|---|---|---|---|---|---|
| Coefficient (ß) | Loco–Regional Control HR (95 % CI) |
p-Value | Coefficient (ß) | Loco–Regional Control HR (95 % CI) |
p-Value | |
| Age (≥57 vs. <57 years [b]) | −0.75 | 0.47 (0.21–1.07) | 0.074 | −1.54 | 0.21 (0.06–0.78) | 0.019 |
| Gender (female vs. male [b]) | 0.11 | 1.12 (0.41–3.04) | 0.83 | 0.67 | 1.96 (0.61–6.26) | 0.26 |
| Tumour localization (oral cavity vs. others [b]) | 1.09 | 2.97 (1.34–6.60) | 0.007 | 0.55 | 1.73 (0.58–5.21) | 0.33 |
| T stage (3, 4 vs. 1, 2 [b]) | 1.13 | 3.10 (1.41–6.81) | 0.004 | 0.55 | 1.73 (0.60–5.03) | 0.31 |
| N stage (2, 3 vs. 0, 1 [b]) | 0.42 | 1.55 (0.69–3.38) | 0.30 | −0.01 | 0.99 (0.33–2.97) | 0.98 |
| Tumour grade (3 vs. 1, 2 [b]) | −0.33 | 0.72 (0.33–1.58) | 0.41 | −0.96 | 0.38 (0.11–1.37) | 0.14 |
| R status (1 vs. 0 [b]) | 0.95 | 2.58 (0.88–7.60) | 0.085 | 0.09 | 1.10 (0.38–31.8) | 0.87 |
| ECE status (1 vs. 0 [b]) | 0.83 | 2.29 (0.98–5.32) | 0.055 | 0.24 | 1.27 (0.35–4.62) | 0.72 |
| Dose (Gy) | 0.07 | 1.08 (0.93–1.25) | 0.32 | 0.07 | 1.08 (0.87–1.33) | 0.51 |
| p16 overexpression (1 vs. 0 [b]) | −1.20 | 0.30 (0.10–0.88) | 0.029 | −1.38 | 0.25 (0.06–1.13) | 0.071 |
| Metagene KRT6 | 0.59 | 1.80 (1.17–2.79) | 0.008 | 0.49 | 1.62 (0.87–3.02) | 0.13 |
| Metagene SPRR1 | 0.49 | 0.57 (0.34–0.98) | 0.004 | 0.21 | 1.23 (0.82–1.86) | 0.32 |
[b] Baseline class.